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Abstract
This is the official guideline endorsed by the specialty associations involved in the care of head and neck cancer
patients in the UK. It provides recommendations on the assessments and interventions for this group of patients
receiving palliative and supportive care.
Recommendations
• Palliative and supportive care must be multidisciplinary. (G)
• All core team members should have training in advanced communication skills. (G)
• Palliative surgery should be considered in selected cases. (R)
• Hypofractionated or short course radiotherapy should be considered for local pain control and for painful bony
metastases. (R)
• All palliative patients should have a functional endoscopic evaluation of swallowing (FEES) assessment of
swallow to assess for risk of aspiration. (G)
• Pain relief should be based on the World Health Organization pain ladder. (R)
• Specialist pain management service involvement should be considered early for those with refractory pain. (G)
• Constipation should be avoided by the judicious use of prophylactic laxatives and the correction of systemic
causes such as dehydration, hypercalcaemia and hypothyroidism. (G)
• Organic causes of confusion should be identified and corrected where appropriate, failing this, treatment with
benzodiazepines or antipsychotics should be considered. (G)
• Patients with symptoms suggestive of spinal metastases or metastatic cord compression must be managed in
accordance with the National Institute for Health and Care Excellence guidance. (R)
• Cardiopulmonary resuscitation is inappropriate in the palliative dying patient. (R)
• ‘Do not attempt cardiopulmonary resuscitation’ orders should be completed and discussed with the patient
and/or the family unless good reasons exist not to do so where appropriate. This is absolutely necessary
when a patient’s care is to be managed at home. (G)
Introduction
Palliative care aims to improve the quality of life (QoL)
of patients and their carers facing the problems asso-
ciated with life threatening illness. This can be achieved
by the prevention and relief of suffering, ensuring
comfort and dignity, by means of early identification,
assessment and management of pain and other, physical,
psychosocial and spiritual issues.
Patients with head and neck cancer are a group in
whom both specialist palliative and supportive care is
especially appropriate whether the treatment intent is
curative or not, since the disease and its treatments
result in a huge burden of morbidity: short and long
term – even lifelong for survivors. In addition to the
physical symptoms, these patients often have very sig-
nificant comorbidities, including tobacco and alcohol
dependence, and complex psychosocial issues.
All professionals caring for head and neck cancer
patients should assess palliative and supportive care
needs in initial treatment planning, and throughout
the illness, and be aware when specialist palliative
care expertise is needed. This may involve core multi-
disciplinary team (MDT) members, social workers,
psychologists etc. Levels of intervention may involve
in-patient, out-patient, day care, home care and tele-
phone advice, from a single, arm’s length intervention
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to a taking over of care. Support provided will need to
accommodate any communication impediment. In turn,
specialist palliative care practitioners need to be aware
of when and how to use palliative interventions such as
surgery, radiotherapy (RT) and chemotherapy. All this
is best achieved by a high level of integration of ser-
vices – team working, including the primary care
team – and excellent communication, with the ‘key
worker’ (usually a specialist nurse) at the centre.
BOX I
MAIN TARGETS FOR PALLIATIVE CARE
INTERVENTIONS IN HEAD AND NECK CANCERS
Medical and surgical treatments
Pain
Hydration and nutrition
Gastrointestinal symptom relief
Anxiety
Agitation
Dysphagia
Dyspnoea
Bleeding
Airway management
Hypercalcaemia
Holistic, psychosocial and complementary
Breaking bad news
Patient aspirations and expectations
Anxiety
Counselling
Psychological support
Emotional support
Support groups
Massage therapy
Aromatherapy
Recommendation
• Palliative and supportive care must be
multidisciplinary (G)
Approaches
Palliative care takes a holistic approach, addressing phys-
ical, psychological, social and spiritual needs of the
patient, their carers and family (Box I). Interventions
whichmay be appropriate to palliative care include onco-
logical and surgical approaches, drug management, psy-
chological support, Allied Health Professional (AHP)
input and complementary therapies. This paper focuses
on medical and surgical interventions for physical symp-
toms, but these should be addressed as part of a wider
holistic and multidisciplinary approach, which includes
concern with psychosocial and spiritual issues.1–3
Whilst the distinctions between physical and psycho-
social symptoms should not be overstated, different
interventions will dominate in each category. Drugs,
anticancer treatments such as RT, surgery and proce-
dures will dominate in the first category, whilst coun-
selling, honest communication, support groups and
complementary therapies will be preferred in the
second. This distinction is not clear-cut, however;
counselling and honest communication are important
parts of pain relief, whilst drugs have a role in the man-
agement of symptoms such as anxiety and depression.
A well-developed multidisciplinary approach, coupled
with an open-minded approach to intervention, is there-
fore essential.
It is the role of the MDT team to discuss treatment
options in all patients. This includes decisions on
who should be treated and what is untreatable
disease. This is a complex issue and although broad
guidelines can be applied each case should be assessed
individually. Radical treatment in advanced or recur-
rent head and neck cancer may be futile and result in
poorer QoL, therefore important decisions need to be
made at presentation about which treatment pathway
to take. The alternative where there is a low chance
of cure is a palliative pathway. Palliative treatments
include surgical and non-surgical interventions with
the intention of slowing disease growth and symptom
control, and extending life with focus purely on
symptom control.
Effective decision making in the palliative setting is
important. The patient and family should adequately
understand the diagnosis and prognosis, especially if
the trajectory changes due to intervention or disease
progression. It should be made clear that symptoms
will be identified and treated and patients should be
asked if there are any new goals for their treatment
since cure is not possible. In other words, the team
should not convey a sense of hopelessness simply
because the goal is not indefinite survival. Hope can
be maintained within the context of the patient’s own
goals whether they are:
• physical – relief of symptoms
• psychological – fear of distress, suffocation,
bleeding or uncontrollable pain at the end of life
• Social – desire to witness a family event, celebrate
a birthday or make a trip.
Symptoms should be actively sought and treated in a
proactive manner, and it should not be assumed or con-
veyed that any new symptom is as uncontrollable as the
tumour itself. Treatment options should be discussed
for the new symptom including those that may not
extend life. Although patient choice is central to the
treatment options taken, the treating clinician should
make recommendations to guide treatment and share
the burden of difficult decisions.
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Recommendation
• All core team members should have training
in advanced communication skills (G)
Symptom control
Surgical palliation
Incurable end-stage head and neck cancer leads to distres-
sing symptoms. Patients may remain active and self-
caring while trying to cope with problems of pain, swal-
lowing, breathing and bleeding. Palliative surgery may be
indicated in such cases. Little high-level evidence is avail-
able to confirm the surgical benefit; however, descriptive
studies support its use in selected cases. Surgery can
reduce primary tumour bulk, reduce pain and bleeding,
improve swallowing, nutrition and improve and airway
(see below). Debulking surgery for advanced neck
disease can achieve symptom control, but major resec-
tions only rarely offer levels of benefit, which justify
the extent of surgical morbidity.
Newer endovascular techniques, including embol-
isation and vessel stenting, may offer symptom
control for bleeding related to major vascular erosion,
and these interventions can be considered in patients
at high risk of erosion of major vessels.
Acute haemorrhage from carotid ‘blow-out’ (erosion
of the carotid vessels) is a distressing end of life event.
Whilst occasional success can be achieved with swift
surgical intervention, many patients succumb rapidly.
In these cases, attempts to reduce the flow of blood
with direct pressure while administering appropriate
rapid acting sedatives (e.g. benzodiazepines) should be
made. Constant verbal support to the patient is a key
to help handle anxiety. Do not leave the patient’s side.
If surgical intervention is considered inappropriate
careful discussion and measured information giving
to the patient (if they wish to participate) or family
members and carers is essential. This should include
the anticipated clinical scenario and an acceptable plan
of care should be devised tomanage these circumstances.
This may include the use of dark towels, anticipatory
prescribing, and may influence preferred place of care.
Recommendations
• Palliative surgery should be considered in
selected cases (R)
• For control of bleeding endovascular stenting
or embolisation should be considered (R)
Non-surgical palliation
Radiotherapy. Debate continues around the optimal
dosage regimen for palliative RT. Low-level evidence
exists for the use of hypofractionation schedules and
short course RT. Other protocols such as those
described by the Radiation Therapy Oncology Group
have also demonstrated benefit. Symptom control can
be achieved in up to 80 per cent of selected patients
with particular response in terms of pain control. No
high-level evidence exists to support one protocol
over another, but case series report benefit. Re-irradi-
ation may be offered but may be associated with
severe radiation toxicity.
A systematic review of RT for painful bone metasta-
ses reports benefit in up to 50 per cent of patients.4
There is evidence to support the use of bisphospho-
nates to aid pain control of bone pain as an additional
step once RT and conventional pharmacology has
been used. The role of the new monoclonal drugs
including RANK – ligand inhibitors (e.g. denosumab)
has yet to be elucidated.
Chemotherapy. This includes the use of platinum-based
agents, 5-fluorouracil and methotrexate, either as mono-
therapy or in combination with RT and demonstrates
benefit in symptom control and QoL measures, but may
increase toxicity and hence side effects from the treat-
ment. Careful consideration of the balance between
benefit and harm must be made on an individual patient
basis. Non-platinum-based agents are reported as confer-
ring symptom control in the selected cases.
Future modalities. Future research will include the role
of taxanes, e.g. paclitaxel, monoclonal antibodies e.g.
cetuximab, newer chemotherapeutic agents, photo-
dynamic therapy and interstitial laser therapy.
Descriptive series report some symptom controls
using these modalities but without any evidence of
improved survival.
Recommendations
• Hypofractionated or short-course RT should
be considered for local pain control and for
painful bony metastases (R)
• Bisphosphonates can be considered for bone
pain following RT (R)
Palliation of dysphagia
Forty per cent of patients with head and neck cancer
suffer from dysphagia. This is due to:
• mechanical obstruction
• functional obstruction
• drug induced side effects
• fistula
• pain.
Assessment of the swallow is essential in palliative head
and neck patients. It is important to establish whether oral
intake is possible and whether it is safe. Aspiration is not
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uncommon and may be silent in up to 40 per cent of
patients, thus the bedside assessment is of limited value.
Functional endoscopic evaluation of swallowing (FEES)
is straightforward, easily repeatable, portable and can
give good information on the aetiology of aspiration as
well as feedback to the patient on trials of preventative
manoeuvres. It can also be useful in the assessment of
ability to deal with different textures and complements
information obtained from videofluoroscopy.
Aspiration does not inevitably mean no oral intake.
A degree of aspiration may be well tolerated and
methods taught to clear the airway after swallowing
can be implemented. Similarly certain textures may
be better tolerated and the use of thickened fluids can
help maintain oral intake. It is important to take into
account the patient’s wishes and the patient may
make an informed choice to continue to swallow
despite the potential and real risk of aspiration pneumo-
nia. Quality of life is absolute.
In patients who are unable to swallow, the use of an
enteral route via nasogastric tube (NGT) or gastrostomy
allows for hydration, nutrition and medication. The type
of tube used depends largely on ability to pass an NGT
or fashion a gastrostomy, perceived duration of use and
patient choice. If enteral nutrition via NGT is likely to
extend beyond two to three weeks then gastrostomy
should be considered and discussed with the patient.
There exists no clear guidance on when or if it is
acceptable to withdraw nutritional support. Patient
and family wishes are crucial in this decision process
and full consultation is imperative.
Conventional treatments can be helpful in the palli-
ation of swallowing. Surgical debulking either with or
without the laser or debrider and RT may help reduce
bulk in a hypopharyngeal tumour, dilatation can help in
stricture formation and this can be surgical or radiologic-
ally guided. Stenting may play a role but often head and
neck tumours are too high to accommodate a stent com-
fortably and without impacting on other functions.
Recommendations
• All palliative patients should have a FEES
assessment of swallow to assess for risk of
aspiration (G)
• Establishment of enteral feeding must be
considered early in patients who are unable to
maintain their intake orally (G)
Palliation of the airway
Where there is airway compromise it is common prac-
tice to consider a tracheostomy. However, it may be
possible to avoid tracheostomy in some cases if the
consideration is given to surgical debulking techniques.
This is dependent on local expertise and equipment.5
Sometimes avoiding surgical intervention is the most
appropriate course of action, for example, a patient with
a tracheal tumour that has been repeatedly debulked,
and has received palliative RT, is not a candidate for
stenting. There will come a time when the airway com-
promise will be life threatening. A tracheostomy may
not be an option in this instance. In such instances
opioids for dyspnoea in addition to palliative sedation
and reduction of secretions can support a patient in a
terminal event.
These situations are difficult and information should
be imparted to the patient sensitively. In the situation
where the patient wants to fully discuss the anticipated
scenario a sense of control can be restored to them by
discussing what interventions can be undertaken
pharmacologically to avoid any distress. If the patient
does not want to participate in the discussion this
should be documented and discussed with family
and/or carers. This situation may influence the pre-
ferred place of care. To have the patient and the
family prepared for the event is paramount. They
must know what will be in place to prevent the dys-
pnoea and anxiety associated with such a situation
and the patient must be comfortable to the end.
If a tracheostomy is indicated local protocols should
exist or be developed to help the patient, the family and
community staff manage tracheostomy wound care
along with maintenance of a clean secure tube. Heat
moisture exchange and voicing attachments may be
used to aid patient communication.
Pain
Pain is very common, affecting most patients at any
stage. It may be disease or treatment related, either
acute and/or immediate or persistent and/or lifelong.
Pain occurring after a long, pain free interval is likely
to be recurrent disease. Assessment must take account
of the presence of ‘total pain’ i.e. physical, spiritual,
psychological and social elements. The three major
pain types are all encountered – somatic, visceral
and, particularly difficult, neuropathic.
Analgesic use is best based on the World Health
Organization (WHO) ‘pain ladder’ (Box II) with
three steps of increasing potency, and used depending
on pain severity and response. The severity of the
pain dictates the strength of the analgesic and the patho-
physiology dictates the adjuvant used.
BOX II
WHO PAIN LADDER
Paracetamol± non-steroidal anti-inflammatory
drug± adjuvant
Weak opioid (codeine or tramadol)+ step 1 drugs
Strong opioid replacing the weak+ step 1 drugs
The choice of formulation depends on whether the
patient can swallow, is vomiting, or has a nasogastric
(NG) or gastrostomy tube in situ.
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Somatic pain. Morphine remains the first choice strong
opioid, other than perhaps in renal impairment when an
alternative is preferred. It is initiated by titrating imme-
diate release morphine oral solution or tablet (e.g.
Oramorph™ solution or Sevredol™ tablet). Once
responsiveness and dosage are known, then sustained
release preparations are used, with immediate release
doses for breakthrough at a sixth of the 24 hour sus-
tained release dosage. If the patient can swallow, then
sustained release tablets (e.g. MST Continus™) or cap-
sules (e.g. Zomorph™) can be used. If a tube is in place
then a morphine suspension (e.g. MST suspension™)
or opened capsules (e.g. Zomorph™) can be used. If
this is not feasible, usually because of vomiting, then
a subcutaneous (SC) infusion of morphine or diamor-
phine can be used, with SC doses for breakthrough.
Diamorphine is preferred since it is more soluble and
can be used in much smaller volumes.
Transdermal preparations of fentanyl have theoretical
and practical attractions for stable background pain as an
alternative, particularly if there is morphine intolerance
(e.g. sedation and dysphoria) or there is renal failure.
For breakthrough pain, oral opioids can still be used.
Alternatively, new preparations of buccal, sublingual
or intranasal fentanyl may have a role in specific situa-
tions, with supervision of a specialist service.
Oxycodone can be an alternative to morphine where
there is intolerance, particularly dysphoria; there is an
immediate release solution and injection, but there is
only a tablet form of sustained release oral preparation,
limiting its use where swallowing is compromised.
Hydromorphone is not useful orally where swallowing
is impossible, both immediate and sustained release
being capsules, but it may be injected. Methadone in
liquid form can be very useful, being rapid in onset
and long acting because of its half-life; it is best used
by specialists as it can accumulate.
Neuropathic pain. This is very common both as a pre-
senting feature of the disease and a result of treatment,
particularly radiation. The drugs used can be referred to
as adjuvants.
• A tricyclic antidepressant, most usually amitriptyl-
ine is available as tablet and liquid.
• Anticonvulsants such as gabapentin and pregaba-
lin are the most used, available only as tablets or
capsules unless through special arrangements
with a pharmacy. Gabapentin can be opened and
administered via the gastrostomy tube.
• Carbamazepine is an alternative and is available
both as tablet, liquid and even suppositories.
Sodium valproate is also available as a liquid
preparation.
First line would be either antidepressant or anticon-
vulsant titrated to maximum dose tolerated (usually
added to a conventional analgesic): second line
would be to use both.
Some advocate corticosteroids (e.g. dexamethasone
8–16 mg daily) as first line for acute neuropathic
pain where there is felt to be a significant inflammatory
component. Appetite stimulation limits use if dyspha-
gia is a concomitant feature. It is not for chronic or pre-
dictably long-term pain. Clonazepam is occasionally
useful. Methadone and ketamine are useful, but only
in specialist settings.
Visceral pain. Treatment depends on the cause, titrating
analgesics and using the pain ladder. If the pain is
poorly sensitive to opioids, adjuvants should be consid-
ered early, for example pain due to metastatic disease in
the liver or nerve compression may be eased with
Dexamethasone (4–8 mg daily).
Judicious use of all these drugs is best achieved by
seeking advice from the specialist palliative care
service whenever there is concern. Interventional pain
techniques can be very effective where systemic treat-
ments fail or if the patient is intolerant of the significant
doses of combination analgesics.
Mucosal pain. This can be due to treatment, infection or
tumour. Treatment of infection such as candida
or herpes is essential. Useful additional topical agents
include sulcralfate, benzydamine, chlorhexidine, ster-
oids and topical local anaesthetics such as lignocaine
preparations. Coating measures including bioadherent
oral gel may be preferred by the individual patient.
Recommendations
• Pain relief should be based on the WHO pain
ladder (R)
• Specialist pain management service
involvement should be considered early for
those with refractory pain (G)
Nausea and vomiting
The approach must take an account of the large number
of patients who are enterally fed. Even with this there is
often a need for injectable anti-emetics – subcutaneous
(SC) boluses or continuous infusions, at least until
initial control is established.
Enteral feeding poses its own challenge, and pro-
kinetic drugs such as metoclopramide (tablet, oral solu-
tion or injection) or domperidone (tablet, suspension or
suppository) may be needed to ensure best function.
Otherwise the approach is similar to that in general
use. Remember the practical issue of providing a
large bowl, tissues and water for the patient and be pre-
pared to rehydrate using IV or SC fluids if appropriate.
Constipation
Constipation develops in half of patients who are ter-
minally ill with cancer admitted to a hospice. In
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addition, it is common during treatment in many
patients. This is due to dehydration, reduced physical
activity and the use of constipating drugs, particularly
opioids and anticholinergic medication. Laxatives
should be initiated once opioid medication is pre-
scribed. Hypercalcaemia and hypothyroidism are
other causes, which may be overlooked.
The principle of treatment is avoidance and early rec-
ognition. Enquiry should be made on patient contact.
Laxative agents include stimulants such as bisacodyl
and senna and softeners such as lactulose, magnesium
hydroxide and docusate. Polyethylene glycol prepara-
tions including movicol and laxido are commonly
used. These should be used prophylactically. If consti-
pation develops it can lead to nausea and vomiting and
in the severe situation pseudobstruction. If rectal exam-
ination reveals hard stool then the use of suppositories
and enemas can be helpful. Ultimately, a manual
evacuation may be necessary.
Recommendation
• Constipation should be avoided by the
judicious use of prophylactic laxatives and the
correction of systemic causes such as
dehydration, hypercalcaemia and
hypothyroidism (G)
Confusion and agitation
It is important to distinguish anxiety (unsettled, frigh-
tened, panic) from confusion, particularly delirium.
Confusion is common, affecting up to 75 per cent of
cancer patients at some stage. Many head and neck
patients have a history of heavy alcohol (and tobacco)
consumption, predisposing them to the effects of
withdrawal, and given that cancer is more commonly
seen in old age; then cognitive impairment is not
uncommon.
Benzodiazepines are the mainstay of pharmacologic-
al treatment of anxiety. Diazepam can be given orally,
via a tube in liquid form, or by injection intravenously.
Lorazepam can be swallowed or a tablet dissolved sub-
lingually. If injections and/or infusions are needed,
midazolam is preferred, as it can be given subcutane-
ously (most common route) or intravenously when
almost immediate effect is needed. The key limiting
factor, however, is rapidly developing tolerance; ben-
zodiazepines are useful for short-term management of
episodes of anxiety, but are limited where anxiety is
pre-existing and established.
Delirium as a cause of confusion can be related to a
number of organic causes – infection, dehydration,
metabolic disturbance, respiratory failure, urinary reten-
tion, constipation, brain metastases, etc. Administered
drugs are common causes, particularly opioids and
drug withdrawal (see above). While treatment has to
be aimed at the cause, symptommanagement is required
in the short term. While benzodiazepines have a role,
indeed a specific indication in drug withdrawal, most
often delirium is better managed using haloperidol (as
tablet, liquid or injection, including SC) or levomepro-
mazine (as tablet or injection) where sedation is
needed in managing paranoia etc.
In some cases, particularly for irreversible agitation
or delirium in a dying patient, benzodiazepines and
antipsychotics need to be combined and are often admi-
nistered using a syringe driver.
Recommendation
• Organic causes of confusion should be
identified and corrected where appropriate,
failing this, treatment with benzodiazepines
or antipsychotics should be considered (G)
Secretions
Although xerostomia is common in these patients,
excess secretions and/or the inability to swallow or
otherwise clear secretions is often troublesome.
Physically the use of suction either by carer or the
patient is often helpful.
There are three widely used antimuscarinic drugs.
• Hyoscine hydrobomide (scopolamine) is available
as a transdermal patch, oral or sublingual tablet
and is commonly used; however, it has central
as well as peripheral actions and (unpredictable)
sedation and/or confusion can result.
• Hyoscine butylbromide, which is not central
nervous system active, but equally effective per-
ipherally, and is arguably the drug of choice. It
is available as a tablet, though often ineffective
by that route; hence SC use may be preferred.
• Glycopyrronium, which is similarly peripherally
active, and is most often given subcutaneously.
A liquid form can be prepared but efficacy is
unpredictable.
• Excess secretions at the end of life are treated simi-
larly, but the evidence in a Cochrane review sug-
gests they are of very limited benefit. Established
practice accepts SC preparations of anticholinergic
medication are available for use to support this end
of life phase. Timely management is a key here; if
secretions develop, then regular or continuous
antisecretory drugs should be started as soon as
practical, rather than relying on PRN drugs.
Steroids
As with other cancers, corticosteroids are widely used.
Dexamethasone (Table I) is the most used, because of
its potency, relative lack of mineralocorticoid properties,
and wide range of formulations (water soluble tablets,
solution, and injection, SC or intravenous).6
Dexamethasone 1mg = Prednisolone 7.5mg
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Long-term use also requires that attention be paid to
bone mineral density, and bisphosphonates, and
calcium and/or vitamin D supplements are indicated.
BOX III
SPINAL METASTASES
Type of associated pain
Pain in spine (new or progressive)
Spinal pain aggravated by straining
Localised spinal tenderness
Pain in spine at night preventing sleep
Neurological symptoms and signs
Radicular pain
Limb weakness
Difficulty walking
Sensory loss
Bladder or bowel dysfunction
Signs of caudal equina/spinal cord compression
If used for any length of timepatientsmust carrya ‘steroid
card’, keep it up to date, and be aware of the advice on it,
i.e. to increase the dose when there is intercurrent illness
or other stressor; and the need to reduce very gradually if
used for more than three to four weeks – including at the
end of life. Some advise that steroids given for poor appe-
tite or fatigue can be discontinued then. This puts the
patient at risk of steroid insufficiency, an unnecessary
symptom burden even at that stage, and dexamethasone
can be given in small volumes subcutaneously once
daily, as part of end of life care if appropriate.
Spinal metastases
The incidence of spinal metastases in head and neck
squamous cell carcinoma is reported to be less than 2
per cent; however, it is more common in thyroid
cancer (2–13 per cent). The most important factor in
determining outcome is neurological status prior to
treatment. Due to the devastating neurological sequelae
of spinal cord or cauda equina compression early rec-
ognition (Box III) and action is essential and consider-
ation that symptoms may be suggestive of spinal
metastatic disease is the first step.7
Neurological symptoms and signs should be
assessed and a magnetic resonance imaging of the
whole spine obtained. This is an oncological emer-
gency and steroids should be commenced while inves-
tigations or admission are arranged. Treatment depends
on findings and includes steroids, surgical stabilisation
and RT. Clear guidelines on diagnosis and manage-
ment have been published by National Institute for
Health and Care Excellence (NICE) and the readers
should familiarise themselves with these.7
Recommendation
• Patients with symptoms suggestive of spinal
metastases or metastatic cord compression
must be managed in accordance with the
NICE guidance (R)
Care of the dying
Care of the dying is an important part of good palliative
care. Dying patients may have significant and rapidly
changing symptoms, together with a recognition that
no further active intervention is appropriate. For these
reasons, timely assessment, regular review and confi-
dent symptom control are essential. In addition, this
is an important time for loved ones; as noted by
Dame Cicely Saunders, ‘How people die remains in
the memories of those who live on’. Ongoing sensitive
and honest communication, coupled with sensible and
proactive decision-making are therefore essential.8
Reversible causes for a patient’s deterioration should
be considered and may be acted upon depending upon
earlier discussions, clinical acumen and based on the
best interests of the patient. The physical changes pre-
ceding death generally include decreasing mobility,
decreasing level of consciousness and interaction,
minimal intake, progressing to no oral intake, decreasing
urine output, haemodynamic deterioration and changes
in respiratory pattern. Recognising death is imminent,
the doctor may lead multiprofessional decision making
and communication ensuring the patient (if appropriate)
and families or carers understand the expected trajectory.
The patient’s values and preferences should be
upheld where possible, these may include rapid dis-
charge to enable the patient to die in the place of
their choice, or enable their family to stay with them
if in in-patient settings. Any religious, spiritual or cul-
tural preferences should be identified.
The Liverpool Care Pathway (LCP) was a protocol
developed at the Marie Curie Institute Liverpool, and in
use in the UK between 1997 and 2014. Concerns about
the use of the pathwaywere raised in the press, and a sub-
sequent government review was undertaken. Whilst
recognising both good and bad outcomes arising from
the use of the pathway, the ultimate recommendation of
the review body was that the LCP be withdrawn.
Current approach is based on this framework but using
a more individualised and tailored care plan. Such
plans are currently subject to local variation but can be
TABLE I
INDICATIONS AND DOSAGE FOR STEROID
(DEXAMETHASONE) USE
Appetite, energy and wellbeing 4 mg initially
Adjuvant analgesic 8–16 mg initially
Anti-emetic See above
Spinal cord compression See NICE
guidelines7
Tumour oedema (e.g. tracheal compression,
superior vena cava obstruction)
8–16 mg initially
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used in all care settings including patient homes.National
guidance is being developed following consultation.
A key role of the doctor is to recognise that death is
imminent, and, as recommended in the government
review, the patient’s senior clinician has a vital role
in this decision in the MDT. Recognition of dying
should prompt a thorough review of all care and inter-
ventions, with unnecessary medication being stopped,
and essential medication continued, usually by SC
infusions and boluses. In the head and neck patient,
the frequent presence of NG and gastrostomy tubes
allows continued use of some medications which
would otherwise be impossible to administer.
It is important to highlight that recognising dying
does not automatically lead to discontinuing any such
interventions; only that their role in improving symp-
toms should be assessed.
Whilst nutrition is usually inappropriate in dying
patients neither SC nor intravenous fluid is necessarily
ruled out – although the benefits can be, indeed often
are very limited. Enteral tubes provide a further
option for those patients.
Sensitive discussion with the patient (if appropriate)
and family or carers should be initiated to dispel any
concerns held and agree a plan appropriate to the indi-
vidual which may require modification depending
upon the timescale and symptoms observed. A
further vital aspect of end of life care, recognised
both in the LCP and the review, is the need for
regular multiprofessional assessment, and the possibil-
ity that patients may improve, for whatever reason, and
hence the management plan be changed.
Whilst an individualised approach is vital for dying
patients, certain symptoms are common enough to
warrant ‘anticipatory prescribing’. The four major
symptoms for which this is appropriate are:
• pain
• nausea and vomiting
• agitation
• excess secretions.
The choice of drugs used is left to individual units
and must be individualised further for some patients.
For most purposes:
• analgesia – diamorphine or morphine
• anti-emetic – haloperidol or levomepromazine
• agitation – midazolam and/or levomepromazine
or haloperidol
• antisecretory – hyoscine, either butyl or
hydrobromide.
Common reasons for modifying the drugs of choice
include poor tolerance of previous drugs, cases where
other drugs have an already-established role, clinical
contra-indications or renal failure. Fortunately, all the
commonly needed drugs can be given subcutaneously,
and feeding tubes increase the available options. Areas
which require ongoing monitoring and vigilance
include mouth care, tracheostomy and wound care,
pressure areas, and continence.
Recommendation
• All patients at the end of life should have
anticipatory medication available to palliate
common symptoms and should have an
individualised care plan (G)
Do not attempt resuscitation (DNAR)
(cardiopulmonary resuscitation (CPR))
This is a subject of such wide clinical and ethical com-
plexity (Box IV and V) that it is not possible to offer
more than a few thoughts on the main points. Such a
decision applies ONLY to the state of cardiopulmonary
arrest – it does not imply withholding other treatments,
including other ‘resuscitation’ measures (e.g. reinsert-
ing a dislodged tracheostomy tube).
BOX IV
FUNDAMENTAL ETHICAL PRINCIPLES
Respect for autonomy
Beneficence
Non-maleficence
Justice
BOX V
RELEVANT ARTICLES OF HUMAN RIGHTS ACT
The right to life
Freedom from inhuman or degrading treatment
The right to privacy
Freedom of expression and to be informed
Freedom from discrimination
When considering palliative and end of life care, one
specific area for consideration is that of CPR.
Ultimately, any decisions made around CPR should
be undertaken in advance. In the event of a cardiac
arrest, and where no such decisions have been made
in advance, the default position is to perform CPR. In
some cases, even in patients with incurable disease,
this is appropriate. In the dying patient, however, or
in cases where the chances of CPR succeeding are
remote, then CPR adds no benefit to patient care. In
such cases, a ‘Do not attempt cardiopulmonary resusci-
tation’ (DNACPR) order should be completed.
There exists a number of issues regarding DNACPR
decisions, outlined in national guidance issued by the
British Medical Association (BMA), Royal College
of Nursing (RCN) and Resuscitation Council (RC),
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and recently examined in a Court of Appeal Judgement.
Two key points stand out – the decision-making
around CPR, and the discussion around such decisions.
The current BMA, RCN and RC guidance is sum-
marised here, but may be subject to review in the
coming months.
Decisions around CPR
Where a cardiac arrest is a significant possibility, where
CPR has a reasonable chance of success, and where
no advance decisions have been made with respect
to resuscitation, then CPR should be attempted.
Examples of such cases include acute reversible ill-
nesses or treatable arrhythmias. Similarly, if a cardiac
arrest is unlikely, then CPR should be attempted if it
occurs. Examples here include the otherwise healthy
person admitted with a relatively minor illness or an
out-of-hospital arrest in public. A presumption of
patient consent exists here, and it is not relevant to
discuss in advance unless requested (and in such a
case, patient wish should be respected). Whilst this is
applicable to many hospital patients, it is less relevant
to palliative care patients, in whom life-threatening
events are more likely, and CPR is less likely to
succeed.
At the other extreme, where a patient is dying and no
reversible causes for their condition exist, then CPR is
inappropriate. In this context, cardiac arrest may be
viewed as the final event in the process of natural
death. Nevertheless, whilst the clinical decision may
be clear, serious consideration needs to be given to dis-
cussion with the patient and family; this is covered in
the section ‘Discussing CPR decisions’, below.
In many cases, including in palliative care, the ben-
efits and burdens of CPR are less clear-cut. For
example, in a patient with an ultimately palliative diag-
nosis but who is otherwise active and well, there is a
small chance that CPR in the event of a cardiac arrest
may succeed. It is beyond the remit of this work to
outline factors that count for and against this. In such
cases, the preferences of patients (or those delegated
to make decisions on their behalf) are pivotal.
Discussing CPR decisions
As outlined above, discussing CPR decisions is not
relevant in a large proportion of hospital patients, as
presumption of consent exists. This section is con-
cerned with those cases where cardiac arrest is a realis-
tic possibility.
Where CPR would not succeed. In cases where it has
been determined clinically that CPR has no realistic
chance of success, the decision rests with the medical
team. Any discussion revolves around sensitively
informing the patient (and/or any person delegated to
be involved in such discussions) of the decision that
has been made. Difficulties here arise where the
patient or delegated person objects to the decision. In
such cases, seeking a second opinion is good practice.
It is usually possible to work through such disagree-
ments with time and sensitive communication.
In some such cases, the cited guidance allows for
DNACPR decisions not to be discussed with the
patient or their delegated decision-maker. This
applies to situations where the treating team have
strong reason to believe that such discussions will
cause significant distress or where the patient has
asked not to be involved in such discussions. Citing
risk of distress should not be undertaken lightly; any
such judgement should be carefully documented and
backed up with evidence – such decisions have been
challenged in court.
It is important to reinforce that the clarity of the deci-
sion is not a factor in considering whether to discuss a
DNACPR order. Even where CPR has no chance of
success, serious consideration should still be given to
discussion.
Unclear benefits/burdens: a person with capacity. A
competent patient can decline CPR and a DNACPR
document can be completed based solely on this deci-
sion, provided the clinician completing the document is
satisfied that the patient has capacity for the decision
and understands it.
Whilst a competent patient may decline CPR, they
may not insist on receiving CPR in the event that
they suffer a cardiac arrest, if it is deemed that CPR
would not succeed. Where there is a possibility of
success, eliciting and respecting the patient’s wish is
crucial. Such discussions should be handled sensitive-
ly, and the patient given the opportunity to consider the
discussion and invite family members/carers to
support them.
There are further subtleties to these decisions, but
such discussion is outside the remit of this work.
Examples include a patient refusing discussion, or a
patient delegating a decision to healthcare profes-
sionals. Current professional guidance is helpful in
working through these situations.9,10
Unclear benefits/burdens: a person with recent loss of
capacity. If the patient has recently lost capacity for
such decisions, some questions need to be asked:
• Have they previously discussed and agreed to a
DNACPR?
• Have they made some other form of advanced
decision to refuse treatment/living will?
• Have they been party to ‘Advance Care
Planning’?
• If so, are the circumstances those previously
envisaged?
It could then be seen as reasonable to let this inform
the current decision. It is also important to know
whether the patient, when competent, appointed
someone with lasting power of attorney under the
terms of the Mental Capacity Act, 2005 – in which
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case this person should be approached, bearing in mind
that they, no more than the patient, can insist on treat-
ment, only decline it – see above.
Unclear benefits/burdens: a person with longstanding
loss of capacity. If the patient has a longstanding loss
of capacity, then the decision is left to the doctor(s)
and other members of the team to act in the patient’s
best interest, in accordance with the provisions of the
Mental Capacity Act. Where available, family, next of
kin and carers can be asked if they are aware of any opi-
nions expressed previously by the patient, etc. – again
noting that they cannot actually make the decision,
only inform the process. In situations where the patient
is alone then under the Mental Capacity Act one must
involve Independent Mental Capacity Advocate to con-
tribute to the decision- making process.
Further considerations
It is not possible to cover all eventualities for these
decisions, and professional guidance exists and
should be followed. Two further issues warrant discus-
sion, however; managing unresolved disagreements
and transfer to the home environment.
Despite the emotive nature of the subject and com-
plexity of decisions, it is usually possible to work
through DNACPR decisions to the agreement of the
patient, their loved ones and the clinical team. As
described above, a second opinion can be helpful in
resolving a disagreement. Occasionally no agreement
can be reached between doctor, the team, the patient
and those close to the patient. In extreme cases, particu-
larly where the patient lacks capacity, legal advice may
be required and consideration given to more formal
measures such as the involvement of the Court of
Protection.
A further point to highlight is the transfer of
DNACPR decisions to the home environment. In such
context, the patient and their family/carers are respon-
sible for the documentation and, as such, are able to
ignore or withhold it if they wish. For this reason,
clear communication and agreement in advance are vital.
Recommendations
• Cardiopulmonary resuscitation is
inappropriate in the palliative dying patient
(R)
• ‘Do not attempt cardiopulmonary
resuscitation’ orders should be completed and
discussed with the patient and/or the family
unless good reasons exist not to do so where
appropriate. This is absolutely necessary
when a patient’s care is to be managed at
home (G)
Key points
• Palliative care takes an holistic approach addres-
sing physical,psychological, social and spiritual
needs of the patient,their carers and family
• Symptoms should be actively sought and treated
in a pro active manner by the multidisciplinary
team
• Pain is very common, affecting most patients at
some point and maybe disease or treatment
related.
• Constipation develops in half of patients who are
terminally ill with cancer admitted to hospice
• Confusion can affect up to 75% of cancer patients
at some stage.
• Spinal metastases should be considered where
there is new or progressive back pain and investi-
gated pro actively
• A key role of the doctor is to recognise when death
is imminent and should prompt a through review
of all care and interventions with unnecessary
medication being stopped.
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